Julia Robinson

Clinical and Science Editor

Julia Robinson is our Senior Data Journalist

High-risk COVID-19 patients may need to seek out own referral for community-based treatment after ‘data mismatch’

Patients eligible for COVID-19 medicines delivery unit treatment are advised to contact their GP or NHS 111 for a referral if they have not been contacted within 24 hours of their positive test result.…

Call for NICE to reverse decision to reject novel osteoporosis drug

The Royal Osteoporosis Society has called on the National Institute for Health and Care Excellence to work with clinicians to ensure patients have equal access to the "life-changing" osteoporosis drug romosozumab.…

Pfizer COVID-19 antiviral paxlovid authorised by MHRA

Paxlovid is the second oral antiviral to be approved for the treatment of mild-to-moderate COVID-19 in high-risk adults, after molnupiravir.…

Hear it here first: a year of the PJ Pod

During our first full year of The PJ Pod, we explored a range of topics including mental health in the face of COVID-19, hidden disabilities in pharmacy and a closer look at the diversity of the MPharm degree.…

UK government promises to address ‘shocking’ women’s health gap

The majority of respondents to a call for evidence on women's health said they did not feel listened to by their healthcare provider.…

Government advisers recommend COVID-19 vaccines for clinically vulnerable children aged 5 to 11 years

The Joint Committee on Vaccination and Immunisation has advised that children aged 5 to 11 years who are in a clinical risk group, or who are household contacts of anyone who is immunosuppressed, should be offered the vaccine.…

Government orders 4.3 million further doses of COVID-19 antivirals

The 1.8 million doses of molnupiravir and 2.5 million doses of PF-07321332/ritonavir are in addition to the courses that were announced in October 2021.…

Boots and PDAU agree final pay deal for Boots pharmacists

The Pharmacists' Defence Association Union has decided not to proceed with a ballot on possible industrial action.…

Dupilumab reduces flare-ups in children with uncontrolled moderate-to-severe asthma, finds study

Using data from 408 children, the rate of type 2 inflammation was lower in those who received duplimab compared to placebo.…

How COVID-19 turned anticoagulation on its head

In an effort to reduce face-to-face consultations during the COVID-19 pandemic, anticoagulation services were encouraged to switch as many patients from warfarin to a direct oral anticoagulant as possible. Here, we investigate how this has been going.…